Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

2.6%

1 terminated/withdrawn out of 39 trials

Success Rate

94.7%

+8.2% vs industry average

Late-Stage Pipeline

15%

6 trials in Phase 3/4

Results Transparency

28%

5 of 18 completed trials have results

Key Signals

1 recruiting5 with results

Enrollment Performance

Analytics

N/A
12(35.3%)
Phase 2
9(26.5%)
Phase 1
7(20.6%)
Phase 4
5(14.7%)
Phase 3
1(2.9%)
34Total
N/A(12)
Phase 2(9)
Phase 1(7)
Phase 4(5)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (39)

Showing 20 of 39 trials
NCT06299878Recruiting

MelPRO-0322 (CRISTINA Trial) [miCrobiome pRedIctS aPD1 effecTivnes In melaNoma pAtietns]

Role: lead

NCT05135546Phase 2Terminated

Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial

Role: collaborator

NCT04353050Not ApplicableUnknown

Atypical MOLes and Melanoma Early Detection Study (MoleMed)

Role: lead

NCT04689282Phase 1Completed

Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders

Role: lead

NCT04252144Not ApplicableUnknown

Study of Dietary Patterns and Food Diversity in Russian GERD Patients

Role: lead

NCT03918213Not ApplicableUnknown

Normative Metrics of High-Resolution Anorectal Manometry With the Use of Solid-State Catheter in a Healthy Russian Cohort

Role: lead

NCT03897296Not ApplicableUnknown

Normative Metrics of High-Resolution Anorectal Manometry With the Use of Water-perfused System in a Healthy Russian Cohort

Role: lead

NCT04025424Unknown

Genetic Predictors of Efficiency and Safety of ICIs in Patients With Different Malignancies (ICIPRESIST-0519)

Role: lead

NCT03829865Unknown

Chicago Classification Normative Metrics in a Healthy Russian Cohort According to High-resolution Esophageal Manometry

Role: lead

NCT02957123Phase 1Completed

Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome

Role: lead

NCT04308980Phase 2Unknown

Safety and Tolerability of Novel Medical Nutrition Products for NAFLD Treatment

Role: lead

NCT03384329Phase 4Completed

Efficacy of Resveratrol in Depression

Role: lead

NCT02967874Phase 1Completed

Autologous Adipose-Derived Stromal Vascular Fraction Cells for Osteoarthritis Treatment

Role: lead

NCT03337165Phase 1Completed

Autologous Tolerogenic Dendritic Cells for Treatment of Patients With Rheumatoid Arthritis

Role: lead

NCT01882088Phase 4Completed

Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD

Role: lead

NCT03119025Phase 1Completed

Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection

Role: lead

NCT01756508Phase 2Completed

Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury

Role: lead

NCT02325947Not ApplicableCompleted

Efficacy of Hand Exoskeleton Controlled by BCI in Post Stroke Patients

Role: lead

NCT01699048Not ApplicableCompleted

The Comparative Effectiveness of Hybrid Revascularization (MIDCAB Then PCI) With DES Versus Multivessel DES PCI or CABG

Role: lead

NCT02562651Phase 2Unknown

Changes in Myocardial Biomechanics and Early Short-term Doxycycline Therapy in Patients With Primary Anterior STEMI

Role: lead